In a report released yesterday, Lorenzo Biasio from Credit Suisse maintained a Hold rating on Illumina (ILMN – Research Report), with a price target of $270.00. The company’s shares closed yesterday at $213.02.
According to TipRanks, Biasio is a 4-star analyst with an average return of 8.2% and a 63.86% success rate. Biasio covers the Healthcare sector, focusing on stocks such as Illumina, Boston Scientific, and Edwards Lifesciences.
In addition to Credit Suisse, Illumina also received a Hold from Robert W. Baird’s Catherine Ramsey Schulte in a report issued on August 12. However, on August 16, Stifel Nicolaus maintained a Buy rating on Illumina (NASDAQ: ILMN).
The company has a one-year high of $524.99 and a one-year low of $173.45. Currently, Illumina has an average volume of 1.52M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Incorporated in 1998, Illumina, Inc. is a California-based company which develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. Its products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The company’s products include microarray scanners, sequencing reagents, and onsite training selector. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting.
Read More on ILMN:
- Analysts Conflicted on These Consumer Goods Names: Redbubble Ltd. (OtherRDBBF) and Treasury Wine Estates Limited (OtherTSRYF)
- Wall Street Analysts Are Bullish on Top Materials Picks
- Morgan Stanley Keeps Their Buy Rating on Santos Limited (STOSF)
- Citigroup Sticks to Its Buy Rating for Medibank Private Ltd. (MDBPF)
- Ottawa Bancorp, Inc. Announces Second Quarter 2022 Results and Cash Dividend